Efficacy of neoadjuvant chemotherapy combined with intraperitoneal hyperthermic chemotherapy in advanced ovarian cancer.

NAC combined with IPHC can significantly reduce the perioperative risk, increase the optimal cytoreduction rate and raise the clinical effective rate of CRS in the treatment of advanced ovarian cancer. Moreover, patients have good tolerance, and both tumor progression and survival of patients are significantly improved.